Last reviewed · How we verify
Aspirin, Atorvastatin, Perindopril
Aspirin, Atorvastatin, and Perindopril are marketed drugs developed by the University of Roma La Sapienza, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their well-established mechanisms and broad therapeutic applications, which have been validated through extensive clinical use. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Aspirin, Atorvastatin, Perindopril |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin, Atorvastatin, Perindopril CI brief — competitive landscape report
- Aspirin, Atorvastatin, Perindopril updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI